Sai Life Sciences IPO listing date: Check objectives, subscription and other key details ahead of debut

Sai Life Sciences listing date: Sai Life Sciences is all set for its stock market debut on the National Stock Exchange (NSE) and BSE on December 18.

The company’s initial public offering (IPO), a book-built offer worth ₹3,042.62 crore, comprised a fresh issue of 1.73 crore shares amounting to ₹950 crore and an offer-for-sale component of 3.81 crore shares, aimed at raising ₹2,092.62 crore. The IPO garnered strong investor interest, with the issue being oversubscribed by 10.26 times.

As the listing date approaches, here are a few things investors should know.

Sai Life Sciences IPO subscription and other details

The mainboard issue was overall subscribed 10.27 times with bids for more than 39.86 crore shares, compared to the 3.88 crore shares on offer.

The qualified institutional buyers (QIBs) showed the highest demand by subscribing their quota 30.93 times, with bids for 33.01 crore shares against the 1.07 crore shares available to them. The non-institutional investors (NIIs) placed bids for 4.15 crore shares against the 84.47 lakh shares on offer, leading to a subscription of 4.92 times in the segment.

The retail portion of the IPO was subscribed 1.37 times, with bids for 2.69 crore shares compared to the 1.97 crore shares set aside for the category.

The promoters of Sai Life Sciences are Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Private Limited, Sunflower Partners, Lily Partners, Marigold Partners and Tulip Partners. Prior to the IPO, the promoters held 40.48% of the company’s shares. The promoter shareholding will decrease to 35.1% following the issue.

The IPO price band was set between ₹522 and ₹549 per share.

The book-running lead managers for this public offer are Kotak Mahindra Capital Company, Jefferies India, Morgan Stanley India and IIFL Securities. Kfin Technologies serves as the registrar for the IPO.

Sai Life Sciences IPO objective

Sai Life Sciences plans to use the net proceeds from the IPO for specific purposes, which include repayment or prepayment, either in full or part, of its outstanding borrowings. In addition, the company will also use the funds for general corporate purposes.

Sai Life Sciences IPO: Listing date and time

Sai Life Sciences’ shares are scheduled to be listed on the National Stock Exchange (NSE) and the BSE on Wednesday, December 18. The stock will start trading at 10 am.

Sai Life Sciences Ltd financials

Sai Life Sciences reported revenue from operations of ₹1,217.1 crore in FY23, which increased to ₹1,465.1 crore in FY24 and ₹675.29 crore for the first half of FY25. The company’s net profit stood at ₹9.98 crore in FY23, rising significantly to ₹82.80 crore in FY24, with ₹28.01 crore reported in H1FY25.

About Sai Life Sciences

Sai Life Sciences Limited, established in 1999, specialises in research, development and manufacturing of small-molecule new chemical entities. It provides services to biotech and global pharmaceutical companies. The company’s services span markets like the US, UK, Europe and Japan.

Sai Life Sciences offers services in chemistry, manufacturing and control (CMC), contract development and manufacturing (CDMO), and contract research organisation (CRO), covering areas like biology, chemistry and drug metabolism.